Table 2 |.
Active research studies and questions pertaining to post-acute COVID-19
| Question | Study name and/or IDa |
|---|---|
| General | |
| What are the long-term sequelae of COVID-19? | COVIDOM (NCT04679584) |
| CO-Qo-ICU (NCT04401111) | |
| MOIST (NCT04525404) | |
| LIINC (NCT04362150) | |
| NCT04411147 | |
| NCT04573062 | |
| NCT04605757 | |
| What are the immunologic, enzymatic, metabolic and radiographic predictors of post-acute COVID-19? | BIOMARK-COVID (NCT04664023) |
| MOIST (NCT04525404) | |
| What are the long-term effects of COVID-19 on health-related quality of life? | COVIDOM (NCT04679584) |
| RECOVER-19 (NCT04456036) | |
| CO-Qo-ICU (NCT04401111) | |
| COREG Extension (NCT04602260) | |
| NCT04586413 | |
| NCT04632355 | |
| What are the long-term effects of COVID-19 on functional exercise capacity? | CO-Qo-ICU (NCT04401111) |
| COREG Extension (NCT04602260) | |
| Pulmonary | |
| Is there a role for antifibrotic therapy for the prevention of development of pulmonary fibrosis and other respiratory complications in COVID-19 survivors? | NCT04652518 |
| NCT04282902 | |
| NCT04541680 | |
| NCT04527354 | |
| Does pulmonary rehabilitation improve pulmonary outcomes in post-acute COVID-19? | NCT04649918 |
| NCT04365738 | |
| NCT04406532 | |
| NCT04642040 | |
| Hematologic | |
| Does extended thromboprophylaxis lead to clinically meaningful benefit with regards to post-hospital discharge VTE in patients with COVID-19? | NCT04508439 |
| COVID-PREVENT (NCT04416048) | |
| Does prolonged thromboprophylaxis lead to clinically meaningful benefit with regards to venous thromboembolic events in outpatients with COVID-19? | ACTIV4 (NCT04498273) |
| PREVENT-HD (NCT04508023) | |
| Do anti-platelets such as aspirin have a role in primary thromboprophylaxis in patients with COVID-19 managed as outpatients? | ACTIV4 (NCT04498273) |
| Cardiovascular | |
| What are the medium- and long-term effects of COVID-19 on biventricular cardiac function? | CO-Qo-ICU (NCT04401111) |
| MOIST (NCT04525404) | |
| Neuropsychiatric | |
| What are the physical examination and brain-imaging characteristics in those with persistent neurological symptoms in post-acute COVID-19? | NCT04564287 |
| What are the long-term psychiatric sequelae of COVID-19? | CO-Qo-ICU (NCT04401111) |
| NCT04632355 | |
| MIND/COVID-19 (NCT04556565) | |
| Renal | |
| What are the short- and long-term renal outcomes and their predictors in COVID-19 survivors? | NCT04353583 |
| CO-Qo-ICU (NCT04401111) | |
| MOIST (NCT04525404) | |
| Gastrointestinal and hepatobiliary | |
| What are the long-term consequences of COVID-19 on gastrointestinal symptoms, post-infection irritable bowel syndrome and dyspepsia? | NCT04691895 |
a
Study IDs are for ClinicalTrials.gov.